Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Mar 17, 2021 6:25pm
122 Views
Post# 32822089

SELL Mass testing DOES NOT WORK - Minister (48% effective)

SELL Mass testing DOES NOT WORK - Minister (48% effective)

Covid-19: Mass testing is inaccurate and gives false sense of security, minister admits

BMJ 2020371 doi: https://doi.org/10.1136/bmj.m4916 (Published 18 December 2020)Cite this as: BMJ 2020;371:m4916

Mass testing of people without covid-19 symptoms is “not an accurate way of screening the general population,” a senior figure at the Department of Health and Social Care 

One of the main rapid tests used is the Innova Lateral Flow SARS-CoV-2 antigen test, which involves a self-administered swab. However, data released from the Liverpool pilot programme showed that this test detected just 48.89% of covid-19 infections in asymptomatic people.

https://www.bmj.com/content/371/bmj.m4916

mpo
<< Previous
Bullboard Posts
Next >>